Sleep Better, Live Brighter
Using advanced biomarkers to improve sleep quality and memory care
Revolutionizing Memory Care Through Sleep
The Circadian Biomarker Therapeutics Consortium (CBTC) is a leading collaborative network dedicated to pioneering research at the intersection of sleep science and molecular biology. By integrating expertise from diverse institutions, we seek to identify precise biological markers that influence human circadian rhythmicity and related neurological health. Our primary mission is to translate these critical biological insights into diagnostic tools and targetable therapeutic strategies for pre-symptomatic detection and risk management of neurodegenerative disease. Through our rigorous research, CBTC seeks to establish new standards of prevention and personalized care for sleep disorders and neurodegenerative disease.
Exploring how to provide better care
To advance our multi-site sleep and biomarker studies, CBTC is actively pursuing funding through the Ontario Research Fund – Research Excellence (ORF-RE) grant alongside key federal health research initiatives. This targeted capital will support our continuous high-density EEG data collection and opening of our first dedicated laboratory space in Hamilton, Ontario. Beyond provincial support, the consortium is expanding its operational capacity through strategic public-private partnerships, institutional co-funding, and targeted clinical trial grants across Canada. By securing these critical resources, CBTC aims to accelerate the translation of early-stage circadian research into validated diagnostic tools and preventative therapies for neurodegenerative disease.
Have Questions?
For inquiries regarding research partnerships, institutional collaborations, or joint clinical trial initiatives, please reach out to our consortium leadership using the contact form below. For all media inquiries please email communications@cbtcresearch.com.